Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liujin Qingwen
- Development stage
- Unknown
- Lead developer
- Shandong Hongjitang Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Liujin Qingwen is a Traditional Chinese Medicine (TCM) granule developed by Shandong Hongjitang Pharmaceutical Group as a Class 1.1 innovative drug. It is primarily indicated for the treatment of influenza and has been extensively studied for its efficacy against respiratory viral infections, including COVID-19. The formulation is designed to clear heat, detoxify, and resolve phlegm, addressing symptoms such as fever, cough, sore throat, and fatigue. Preclinical and clinical studies suggest that Liujin Qingwen exerts its therapeutic effects through a multi-target mechanism, including the inhibition of viral replication and the modulation of the host's inflammatory response by reducing the production of pro-inflammatory cytokines. It has progressed through Phase 3 clinical trials in China for both influenza and COVID-19 indications.
- Brand names
- Liujin Qingwen
- Other names
- Liujin Qingwen Granules六金清瘟颗粒
02
Targets
CCR5 (C-C chemokine receptor type 5)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Liujin Qingwen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liujin Qingwen.